Difference between revisions of "Trastuzumab deruxtecan (Enhertu)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
(17 intermediate revisions by 2 users not shown)
Line 5: Line 5:
 
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], MedScape,[http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref>[https://www.enhertuhcp.com/en/ Enhertu manufacturer's website]</ref>
 
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], MedScape,[http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref>[https://www.enhertuhcp.com/en/ Enhertu manufacturer's website]</ref>
  
−
==Diseases for which it is established ''(work in progress)''==
+
==Diseases for which it is established==
 
*[[Breast_cancer,_HER2-positive|HER2+ breast cancer]]
 
*[[Breast_cancer,_HER2-positive|HER2+ breast cancer]]
 
*[[Gastric cancer, HER2-positive|HER2+ gastric cancer]]
 
*[[Gastric cancer, HER2-positive|HER2+ gastric cancer]]
−
*[[Non-small_cell_lung_cancer,_HER2-mutated|HER2-mutant NSCLC]]
 
  
 
==Diseases for which it is used==
 
==Diseases for which it is used==
 
*[[Colorectal cancer, HER2-positive|HER2+ colorectal cancer]]
 
*[[Colorectal cancer, HER2-positive|HER2+ colorectal cancer]]
 +
*[[Non-small_cell_lung_cancer,_HER2-mutated|HER2-mutant NSCLC]]
  
 
==History of changes in FDA indication==
 
==History of changes in FDA indication==
 
===[[Breast_cancer,_HER2-positive|HER2+ breast cancer]]===
 
===[[Breast_cancer,_HER2-positive|HER2+ breast cancer]]===
−
*12/20/2019: Granted accelerated approval for patients with unresectable or metastatic [[Biomarkers#HER2|HER2]]-[[Biomarkers#Overexpression|positive]] [[breast cancer]] who have received two or more prior anti-HER2-based regimens in the metastatic setting. ''(Based on DESTINY-Breast01)''
+
*2019-12-20: Granted accelerated approval for patients with unresectable or metastatic [[Biomarkers#HER2|HER2]]-[[Biomarkers#Overexpression|positive]] [[breast cancer]] who have received two or more prior anti-HER2-based regimens in the metastatic setting. ''(Based on DESTINY-Breast01)''
−
*5/4/2022: Approved for adult patients with unresectable or metastatic [[Biomarkers#HER2|HER2]]-[[Biomarkers#Overexpression|positive]] [[breast cancer]] who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within 6 months of completing therapy. ''(Converted to full approval; Based on DESTINY-Breast03)''
+
**2022-05-04: Regular approval for adult patients with unresectable or metastatic [[Biomarkers#HER2|HER2]]-[[Biomarkers#Overexpression|positive]] [[breast cancer]] who have received a prior anti-HER2-based regimen in the metastatic setting. ''(Converted to full approval; Based on DESTINY-Breast03)''
−
*8/5/2022: Approved for adult patients with unresectable or metastatic [[Biomarkers#HER2|HER2]]-[[Biomarkers#Low|low (IHC 1+ or IHC 2+/ISH‑)]] [[breast cancer]] who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy. ''(Based on DESTINY-Breast04)''
+
**2022-05-04: Regular approval for adult patients with unresectable or metastatic [[Biomarkers#HER2|HER2]]-[[Biomarkers#Overexpression|positive]] [[breast cancer]] who have received a prior anti-HER2-based regimen in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within 6 months of completing therapy. ''(Converted to full approval; Based on DESTINY-Breast03)''
 +
*2022-08-05: Approved for adult patients with unresectable or metastatic [[Biomarkers#HER2|HER2]]-[[Biomarkers#Low|low (IHC 1+ or IHC 2+/ISH-)]] [[breast cancer]] who have received a prior chemotherapy in the metastatic setting. ''(Based on DESTINY-Breast04)''
 +
*2022-08-05: Approved for adult patients with unresectable or metastatic [[Biomarkers#HER2|HER2]]-[[Biomarkers#Low|low (IHC 1+ or IHC 2+/ISH-)]] [[breast cancer]] who have developed disease recurrence during or within six months of completing adjuvant chemotherapy. ''(Based on DESTINY-Breast04)''
 +
 
 +
===[[Gastric cancer, HER2-positive|HER2+ gastric cancer]]===
 +
*2021-01-15: Approved for adult patients with locally advanced or metastatic [[Biomarkers#HER2|HER2]]-[[Biomarkers#Overexpression|positive]] [[Gastric cancer|gastric or gastroesophageal (GEJ) adenocarcinoma]] who have received a prior trastuzumab-based regimen. ''(Based on DESTINY-Gastric01)''
 +
 
 +
===[[Non-small_cell_lung_cancer,_HER2-mutated|HER2-mutant NSCLC]]===
 +
*2022-08-11: Granted accelerated approval for adult patients with unresectable or metastatic [[non-small cell lung cancer|non-small cell lung cancer (NSCLC)]] whose tumors have activating [[Biomarkers#HER2|human epidermal growth factor receptor 2 HER2 (ERBB2)]] mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy. ''(Based on DESTINY-Lung02)''
 +
 
 +
===[[Malignant solid neoplasm, ERBB2-mutated|HER2+ solid tumors]]===
 +
*2024-04-05: Granted accelerated approval for adult patients with unresectable or metastatic [[Malignant solid neoplasm, ERBB2-mutated|HER2-positive (IHC3+) solid tumors]] who have received prior systemic treatment and have no satisfactory alternative treatment options. ''(Based on DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02)''
 +
 
 +
==History of changes in EMA indication==
 +
===[[Breast_cancer,_HER2-positive|HER2+ breast cancer]]===
 +
*2021-01-18: Initial conditional authorization
 +
*Uncertain date: Enhertu as monotherapy is conditionally indicated for the treatment of adult patients with unresectable or metastatic [[Biomarkers#HER2|HER2]] [[Biomarkers#Overexpression|positive]] [[breast cancer]] who have received one or more prior anti HER2 based regimens.
 +
*2023-02-16: Enhertu as monotherapy is conditionally indicated for the treatment of adult patients with unresectable or metastatic HER2-low [[breast cancer]] who have received prior chemotherapy in the metastatic setting.
 +
*2023-02-16: Enhertu as monotherapy is conditionally indicated for the treatment of adult patients with unresectable or metastatic HER2-low [[breast cancer]] who developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.
 +
===[[Gastric cancer, HER2-positive|HER2+ gastric cancer]]===
 +
*2023-02-16: Enhertu as monotherapy is conditionally indicated for the treatment of adult patients with advanced HER2-positive [[Gastric cancer|gastric or gastroesophageal junction (GEJ) adenocarcinoma]] who have received a prior trastuzumab-based regimen.
 +
===[[Non-small_cell_lung_cancer,_HER2-mutated|HER2-mutant NSCLC]]===
 +
*Future date (positive CHMP opinion): Enhertu as monotherapy is indicated for the treatment of adult patients with advanced NSCLC whose tumours have an activating HER2 (ERBB2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.
 +
 
 +
==History of changes in Health Canada indication==
 +
*2021-04-15: Initial notice of compliance with conditions for the treatment of adult patients with unresectable or metastatic [[Biomarkers#HER2|HER2]]-[[Biomarkers#Overexpression|positive]] [[breast cancer]] who have received prior treatment with trastuzumab emtansine (T-DM1).
 +
==History of changes in PMDA indication==
 +
===[[Breast_cancer,_HER2-positive|HER2+ breast cancer]]===
 +
*2020-03-25: Conditional new approval for the treatment of unresectable or recurrent HER2-positive [[breast cancer]] in patients who have previously been treated with chemotherapy (for use only if refractory or intolerant to standard therapies).
 +
*2020-03-25: Newly indicated for the treatment of unresectable or recurrent HER2-positive [[breast cancer]] in patients who have previously been treated with chemotherapy (for use only if refractory or intolerant to standard therapies).
 +
*2022-11-24: New indication for the treatment of unresectable or recurrent HER2-positive [[breast cancer]] in patients who have previously been treated with chemotherapy.
  
 
===[[Gastric cancer, HER2-positive|HER2+ gastric cancer]]===
 
===[[Gastric cancer, HER2-positive|HER2+ gastric cancer]]===
−
*1/15/2021: Approved for adult patients with locally advanced or metastatic [[Biomarkers#HER2|HER2]]-[[Biomarkers#Overexpression|positive]] [[Gastric cancer|gastric or gastroesophageal (GEJ) adenocarcinoma]] who have received a prior trastuzumab-based regimen. ''(Based on DESTINY-Gastric01)''
+
*2020-09-25: New indication and a new dosage for the treatment of unresectable advanced or recurrent HER2-positive [[gastric cancer]] that has progressed after cancer chemotherapy.
  
 
===[[Non-small_cell_lung_cancer,_HER2-mutated|HER2-mutant NSCLC]]===
 
===[[Non-small_cell_lung_cancer,_HER2-mutated|HER2-mutant NSCLC]]===
−
*8/11/2022: Granted accelerated approval for adult patients with unresectable or metastatic [[non-small cell lung cancer|non-small cell lung cancer (NSCLC)]] whose tumors have activating [[Biomarkers#HER2|human epidermal growth factor receptor 2 HER2 (ERBB2)]] mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy. ''(Based on DESTINY-Lung02)''
+
*2023-08-23: New indication for the treatment of unresectable advanced or recurrent HER2 (ERBB2) mutation-positive [[non-small cell lung cancer]] that has progressed after cancer chemotherapy.
  
−
== Patient Drug Information==
+
==Patient Drug Information==
 
*[https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761139s000lbl.pdf Fam-trastuzumab deruxtecan (Enhertu) Package Insert]<ref>[https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761139s000lbl.pdf Fam-trastuzumab deruxtecan (Enhertu) Package Insert]</ref>
 
*[https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761139s000lbl.pdf Fam-trastuzumab deruxtecan (Enhertu) Package Insert]<ref>[https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761139s000lbl.pdf Fam-trastuzumab deruxtecan (Enhertu) Package Insert]</ref>
  
 
==Also known as==
 
==Also known as==
 
*'''Code name:''' DS-8201a
 
*'''Code name:''' DS-8201a
−
*'''Generic name:''' fam-trastuzumab deruxtecan-nxki
+
*'''Generic name:''' fam-trastuzumab deruxtecan-nxki, T-DXd
 
*'''Brand name:''' Enhertu
 
*'''Brand name:''' Enhertu
  
Line 39: Line 69:
 
[[Category:Protein expression-specific medications]]
 
[[Category:Protein expression-specific medications]]
  
−
[[Category:Antibody-drug conjugates]]
+
[[Category:Anti-HER2 antibody-drug conjugates]]
−
[[Category:Anti-HER2 antibodies]]
+
[[Category:Topoisomerase I inhibitors]]
−
[[Category:Topoisomerase inhibitors]]
 
  
 
[[Category:Breast cancer medications]]
 
[[Category:Breast cancer medications]]
Line 47: Line 76:
 
[[Category:Gastric cancer medications]]
 
[[Category:Gastric cancer medications]]
 
[[Category:Non-small cell lung cancer medications]]
 
[[Category:Non-small cell lung cancer medications]]
 +
[[Category:Malignant solid neoplasm, ERBB2-mutated medications]]
 +
 
[[Category:FDA approved in 2019]]
 
[[Category:FDA approved in 2019]]
−
[[Category:EMA approved in 2020]]
+
[[Category:EMA approved in 2021]]
 +
[[Category:Health Canada approved in 2021]]
 +
[[Category:PMDA approved in 2020]]

Revision as of 03:52, 1 June 2024

General information

Class/mechanism from the NCI Drug Dictionary: An antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (ERBB2; EGFR2; HER2) conjugated to a derivative of the camptothecin analog exatecan (DXd; DX-8951 derivative), a DNA topoisomerase 1 (topoisomerase I; Top1) inhibitor, with potential antineoplastic activity. Upon administration of anti-HER2 ADC conjugate DS-8201a, the antibody moiety targets and binds to HER2 on tumor cells. Upon antibody/antigen binding and internalization, the DX-8951 derivative moiety binds to and inhibits Top1-DNA complexes, which results in an inhibition of DNA replication, cell cycle arrest and tumor cell apoptosis. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types. In addition, DS-8201a induces antibody-dependent cell-mediated cytotoxicity (ADCC) and causes a bystander killing effect, thereby killing neighboring HER2-expressing tumor cells.
Route: IV

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, MedScape,UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is established

Diseases for which it is used

History of changes in FDA indication

HER2+ breast cancer

  • 2019-12-20: Granted accelerated approval for patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. (Based on DESTINY-Breast01)
    • 2022-05-04: Regular approval for adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen in the metastatic setting. (Converted to full approval; Based on DESTINY-Breast03)
    • 2022-05-04: Regular approval for adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within 6 months of completing therapy. (Converted to full approval; Based on DESTINY-Breast03)
  • 2022-08-05: Approved for adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior chemotherapy in the metastatic setting. (Based on DESTINY-Breast04)
  • 2022-08-05: Approved for adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have developed disease recurrence during or within six months of completing adjuvant chemotherapy. (Based on DESTINY-Breast04)

HER2+ gastric cancer

HER2-mutant NSCLC

HER2+ solid tumors

  • 2024-04-05: Granted accelerated approval for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. (Based on DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02)

History of changes in EMA indication

HER2+ breast cancer

  • 2021-01-18: Initial conditional authorization
  • Uncertain date: Enhertu as monotherapy is conditionally indicated for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received one or more prior anti HER2 based regimens.
  • 2023-02-16: Enhertu as monotherapy is conditionally indicated for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting.
  • 2023-02-16: Enhertu as monotherapy is conditionally indicated for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.

HER2+ gastric cancer

HER2-mutant NSCLC

  • Future date (positive CHMP opinion): Enhertu as monotherapy is indicated for the treatment of adult patients with advanced NSCLC whose tumours have an activating HER2 (ERBB2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.

History of changes in Health Canada indication

  • 2021-04-15: Initial notice of compliance with conditions for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received prior treatment with trastuzumab emtansine (T-DM1).

History of changes in PMDA indication

HER2+ breast cancer

  • 2020-03-25: Conditional new approval for the treatment of unresectable or recurrent HER2-positive breast cancer in patients who have previously been treated with chemotherapy (for use only if refractory or intolerant to standard therapies).
  • 2020-03-25: Newly indicated for the treatment of unresectable or recurrent HER2-positive breast cancer in patients who have previously been treated with chemotherapy (for use only if refractory or intolerant to standard therapies).
  • 2022-11-24: New indication for the treatment of unresectable or recurrent HER2-positive breast cancer in patients who have previously been treated with chemotherapy.

HER2+ gastric cancer

  • 2020-09-25: New indication and a new dosage for the treatment of unresectable advanced or recurrent HER2-positive gastric cancer that has progressed after cancer chemotherapy.

HER2-mutant NSCLC

  • 2023-08-23: New indication for the treatment of unresectable advanced or recurrent HER2 (ERBB2) mutation-positive non-small cell lung cancer that has progressed after cancer chemotherapy.

Patient Drug Information

Also known as

  • Code name: DS-8201a
  • Generic name: fam-trastuzumab deruxtecan-nxki, T-DXd
  • Brand name: Enhertu

References

  1. ↑ Enhertu manufacturer's website
  2. ↑ Fam-trastuzumab deruxtecan (Enhertu) Package Insert
Retrieved from "https://hemonc.org/w/index.php?title=Trastuzumab_deruxtecan_(Enhertu)&oldid=86128"